Diagnostics and therapeutics for early-onset menopause

Abstract

A method of predicting whether a subject is predisposed to developing early-onset menopause is provided. The method involves genotyping a patient at the IL-1 gene loci.

Description

[0001] This application is a divisional of U.S. Ser. No. 09 / 632,657 filed Aug. 4, 2000, now U.S. Pat. No. 6,730,476, which is a continuation in part of U.S. Pat. No. 6,268,142, filed Jun. 30, 1999 the contents of which are incorporated herein by reference in their entireties.1. BACKGROUND OF THE INVENTION[0002] Menopause is defined as the permanent cessation of menstruation caused by failure of ovarian follicular development in the presence of elevated gonadotrophin levels. Comprehensive Gynecology (eds. Mishell et al 1997). A hallmark of menopause is the decrease in ovarian follicular estrogen synthesis, although this is only one aspect of the array of physiological events that accompanies the climacteric. Symptoms accompanying menopause vary from woman to woman, but usually include some component of vasomotor instability or hot flashes, often accompanied by psychological symptoms like mood swings and irritability. The loss of estrogen predisposes to coronary artery disease. Loss o...

AI Technical Summary

Benefits of technology

[0016] In another aspect, the invention features kits for performing the above-described assays. The kit can include nucleic acid sample collection means and a means for determining whether a subject carries an EOM associated allele. The kit may also comprise control samples, either negative or positive, or standards and / or an algorithmic device for assessing the results, and addition reagents and components, including DNA amplification reagents, DNA polymerases, nucleic acid purification reagents, restriction enzymes, buffers, a nucleic acid sampling device, deoxynucleotides, etc. Information obtained using the assays and kits described herein is useful for example for family planning and for treating or preventing the development of symptoms, which are associated with menopause (e.g. osteoporosis and coronary artery disease). In addition, the information can allow a more customized approach to delaying the onset of or treating the symptoms associated with EOM. For example, this information can enable a doctor to: 1) more effectively prescribe a drug that will address the molecular basis of EOM in the subject; and / or 2) better determine the appropriate dosage of a particular drug for the particular patient.

Problems solved by technology

Loss of estrogen further results in loss of overall bone mineral content caused by an increased resorption of bone without a correlative increase in bone formation.

These symptoms represent formidable challenges to the health care system.

In such a patient, hormonal analysis may not yield a diagnosis until after EOM has taken place.

Hormone assays in a younger patient may only be transiently abnormal prior to the onset of permanent ovarian failure.

Images